Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 21, 2004, Pages 5389-5394

  Cumming, John G ^a   McKenzie, Caroline L ^a   Bowden, Stuart G ^a   Campbell, Douglas ^a   Masters, David J ^a   Breed, Jason ^a   Jewsbury, Philip J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

p38 MAP kinase inhibitors

Indexed keywords

ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BINDING SITES; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PYRIMIDINES; QUINAZOLINES; RATS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 5444244504     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.08.007     Document Type: Article

References (33)

1. Etanercept: B. Jarvis, and D. Faulds Drugs 57 1999 945
2. Infliximab: R. Maini, E.W. St. Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky Lancet 354 1999 1932
3. J.C. Lee, J.T. Laydon, P.C. McDonnell, T.F. Gallagher, S. Kumar, D. Green, D. McNulty, M.J. Blumenthal, J.R. Heys, S.W. Landvatter, J.E. Strickler, M.M. McLaughlin, I.R. Siemens, S.M. Fisher, G.P. Livi, J.R. White, J.L. Adams, and P.R. Young Nature 372 1994 739
4. J.C. Boehm, and J.L. Adams Exp. Opin. Ther. Patents 10 2000 25
5. J. Regan, A. Capolino, P.F. Cirillo, T. Gilmore, A.G. Graham, E.R. Hickey, R.R. Kroe, J. Madwed, M. Moriak, R. Nelson, C.A. Pargellis, A. Swinamer, C. Torcellini, M. Tsang, and N. Moss J. Med. Chem. 45 2002 2994
6. P.F. Jackson, and J.L. Bullington Curr. Top. Med. Chem. 2 2002 1011
7. P.F. Cirillo, C. Pargellis, and J. Regan Curr. Top. Med. Chem. 2 2002 1021
8. S. Kumar, J. Boehm, and J.C. Lee Nature Rev. Drug Disc. 2 2003 717
9. J.C. Lee, S. Kassis, S. Kumar, A. Badger, and J.L. Adams Pharmacol. Ther. 82 1999 389
10. S.C. Armstrong Cardiovascular Res. 61 2004 427
11. W. de Boer Expert Opin. Invest. Drugs 12 2003 1067
12. D.J. Hele, and M.G. Belvis Expert Opin. Invest. Drugs 12 2003 5
13. E. Irusen, J.G. Matthews, A. Takahashi, P.J. Barnes, K.F. Chung, and I.M. Adcock J. Allergy Clin. Immunol. 109 2002 649
14. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, L. Henthorn, and L. Richards Bioorg. Med. Chem. Lett. 11 2001 1911
15. For in vitro assay experimental procedures see Ref. 7
16. Cumming, J. G. WO 0020402, 2000
17. Chem. Abstr. 132 2000 265207
18. D.S. Brown, A.J. Belfield, G.R. Brown, D. Campbell, A. Foubister, D.J. Masters, K.G. Pike, W.L. Snelson, and S.L. Wells Bioorg. Med. Chem. Lett. 14 2004 previous communication in this issue. doi:10.1016/j.bmcl.2004.08.006
19. Cumming, J. G. WO 0127089, 2000
20. Chem. Abstr. 134 2000 295834
21. G.A. Breault, R.P.A. Ellston, S. Green, S.R. James, P.J. Jewsbury, C.J. Midgley, R.A. Pauptit, C.A. Minshull, J.A. Tucker, and J.E. Pease Bioorg. Med. Chem. Lett. 13 2003 2961
22. For further information on kinases and assay protocols see: S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Biochem. J. 351 2000 95
23. Work carried out on behalf of AstraZeneca by Sir Philip Cohen, Division of Signal Transduction Therapy, University of Dundee, Dundee, UK. The kinase panel used was the Core panel shown in Table 1 of Ref. 11
24. For an example of this type of method see: W.A. Korfmacher, K.A. Cox, K.J. Ng, J. Veals, Y. Hsieh, S. Wainhaus, L. Broske, D. Prelusky, A. Nomeir, and R.E. White Rapid Commun. Mass Spectrom. 15 2001 335
25. Procedure for rat in vivo LPS model: Female Alderley Park rats (five per group) were dosed orally with the test compound (10 mg/kg; formulated in 1:1 v/v PEG/water; 0.2 mL per 100 g body weight) 60 min prior to challenge with LPS administered intravenously [LPS E.Coli 0111:B4; Sigma L-4130; 30 μg in 0.2 mL sterile physiological saline (Phoenix Pharma Ltd)]. Control animals received vehicle alone prior to LPS challenge. Blood was obtained 60 min after LPS challenge and plasma isolated and stored at -80°C. TNFα concentration was measured by ELISA (R&D Systems rat TNF-α Quantikine kit, catalogue no. SRTA00). For each compound/dose the percentage inhibition of TNFα was calculated as a percentage of controls
26. Zimmitti, C. S.; Shwartz, R.; Torcellini, C. A.; Pargellis, C. A.; Madwed, J. B.; Weldon, S. M. Poster #367, American College of Rheumatology Annual Scientific Meeting, San Francisco, CA, 11-15 November 2001
27. K.P. Wilson, P.G. McCaffrey, K. Hsiao, S. Pazhanisamy, V. Galullo, G.W. Bemis, M.J. Fitzgibbon, P.R. Caron, M.A. Murcko, and M.S.-S. Su Chem. Biol. 4 1997 423
28. L. Tong, S. Pav, D.M. White, S. Rogers, K.M. Crane, C.L. Cywin, M.L. Brown, and C.A. Pargellis Nat. Struct. Biol. 4 1997 311
29. C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham, P.M. Grob, E.R. Hickey, N. Moss, S. Pav, and J. Regan Nat. Struct. Biol. 9 2002 268
30. C.E. Fitzgerald, S.B. Patel, J.W. Becker, P.M. Cameron, D. Zaller, V.B. Pikounis, S.J. O'Keefe, and G. Scapin Nat. Struct. Biol. 10 2003 764
31. L. Shewchuk, A. Hassell, B. Wisely, W. Rocque, W. Holmes, J. Veal, and L.F. Kuyper J. Med. Chem. 43 2000 133
32. Wilson, K. P.; G. W.; Fitzgibbon, M. J.; Caron, P. R.; Griffith, J. P.; Chen, W.; McCaffrey, P. G.; Chambers, S. P.; Su, M. S.-S. J. Biol. Chem. 1996, 271, 27696
33. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Science 289 2000 1938